

Ingeborg Tinhofer

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2639885/ingeborg-tinhofer-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

30
papers

394
citations

10
h-index

19
g-index

30
ext. papers

548
ext. citations

5.7
avg, IF

3.96
L-index

#	Paper	IF	Citations
30	Pilot investigation on the dose-dependent impact of irradiation on primary human alveolar osteoblasts in vitro. <i>Scientific Reports</i> , 2021 , 11, 19833	4.9	0
29	Tumor DNA-methylome derived epigenetic fingerprint identifies HPV-negative head and neck patients at risk for locoregional recurrence after postoperative radiochemotherapy. <i>International Journal of Cancer</i> , 2021 , 150, 603	7.5	
28	Fever range whole body hyperthermia for re-irradiation of head and neck squamous cell carcinomas: Final results of a prospective study. <i>Oral Oncology</i> , 2021 , 116, 105240	4.4	4
27	Establishment and Validation of CyberKnife Irradiation in a Syngeneic Glioblastoma Mouse Model. <i>Cancers</i> , 2021 , 13,	6.6	3
26	Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC. <i>International Journal of Cancer</i> , 2020 , 147, 2293-2302	7.5	5
25	Comparison of GeneChip, nCounter, and Real-Time PCR-Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma. <i>Journal of Molecular Diagnostics</i> , 2020 , 22, 801-810	5.1	1
24	Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer. <i>Oncotarget</i> , 2020 , 11, 3688-3697	3.3	10
23	A FDG-PET radiomics signature detects esophageal squamous cell carcinoma patients who do not benefit from chemoradiation. <i>Scientific Reports</i> , 2020 , 10, 17671	4.9	10
22	⁶⁸ Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer. <i>PLoS ONE</i> , 2020 , 15, e0240892	3.7	7
21	Preclinical models of head and neck squamous cell carcinoma for a basic understanding of cancer biology and its translation into efficient therapies. <i>Cancers of the Head & Neck</i> , 2020 , 5, 9	5.9	6
20	PET measured hypoxia and MRI parameters in re-irradiated head and neck squamous cell carcinomas: findings of a prospective pilot study. <i>F1000Research</i> , 2020 , 9, 1350	3.6	2
19	Prognostic Factors Predict Oncological Outcome in Older Patients With Head and Neck Cancer Undergoing Chemoradiation Treatment. <i>Frontiers in Oncology</i> , 2020 , 10, 566318	5.3	1
18	⁶⁸ Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer 2020 , 15, e0240892		
17	⁶⁸ Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer 2020 , 15, e0240892		
16	⁶⁸ Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer 2020 , 15, e0240892		
15	⁶⁸ Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer 2020 , 15, e0240892		
14	Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 1443-1454	7.4	6

13	Novel prognostic clinical factors and biomarkers for outcome prediction in head and neck cancer: a systematic review. <i>Lancet Oncology, The</i> , 2019 , 20, e313-e326	21.7	67
12	Multilayered Omics-Based Analysis of a Head and Neck Cancer Model of Cisplatin Resistance Reveals Intratumoral Heterogeneity and Treatment-Induced Clonal Selection. <i>Clinical Cancer Research</i> , 2018 , 24, 158-168	12.9	33
11	The role of Next-Generation Sequencing in tumoral radiosensitivity prediction. <i>Clinical and Translational Radiation Oncology</i> , 2017 , 3, 16-20	4.6	6
10	MiR-200b and miR-155 as predictive biomarkers for the efficacy of chemoradiation in locally advanced head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2017 , 77, 3-12	7.5	34
9	Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer. <i>International Journal of Cancer</i> , 2017 , 141, 1215-1221	7.5	17
8	Patient and treatment-related risk factors for osteoradionecrosis of the jaw in patients with head and neck cancer. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2016 , 121, 215-21.e1	2	49
7	Mutational load and mutational patterns in relation to age in head and neck cancer. <i>Oncotarget</i> , 2016 , 7, 69188-69199	3.3	20
6	Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer. <i>Oncotarget</i> , 2016 , 7, 85349-85364	3.3	63
5	Spheroid Culture of Head and Neck Cancer Cells Reveals an Important Role of EGFR Signalling in Anchorage Independent Survival. <i>PLoS ONE</i> , 2016 , 11, e0163149	3.7	19
4	The rationale for including immune checkpoint inhibition into multimodal primary treatment concepts of head and neck cancer. <i>Cancers of the Head & Neck</i> , 2016 , 1, 8	5.9	6
3	CCI-779 (Temsirrolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab. <i>Journal of Translational Medicine</i> , 2015 , 13, 106	8.5	11
2	Next-generation sequencing: hype and hope for development of personalized radiation therapy?. <i>Radiation Oncology</i> , 2015 , 10, 183	4.2	8
1	Increased growth-inhibitory and cytotoxic activity of arsenic trioxide in head and neck carcinoma cells with functional p53 deficiency and resistance to EGFR blockade. <i>PLoS ONE</i> , 2014 , 9, e98867	3.7	6